# Clinical Trials Data ALK - Document 19

# The Anti-Diabetic and Cholesterol-Lowering Effects of Cinnamon and Cassia Bark

## Clinical Trial: https://clinicaltrials.gov/study/NCT00479973

"eligibilityCriteria": "Inclusion Criteria:\n\n\* Diagnosed with type 2 diabetes\n\* Aged \\> 30\n\* Male or female\n\* Not taking anti-diabetic or lipid-lowering medication OR on a stable drug regimen for at least 3 months without any planned dosage change by the participants attending physician\n\* Have fasting blood glucose at or between 8-15 mmol/L\n\* Not taking any medications or natural health products that may affect serum parameters tested\n\* Having already been educated in exercise and dietary changes known to improve glucose control\n\nExclusion Criteria:\n\n\* Type 1 diabetics\n\* Patients taking insulin\n\* Pregnant or planned pregnancy\n\* Breastfeeding\n\* Known allergy to ingredients in Cinnamonforce\n\* Patients with underlying heart, liver, kidney, endocrine or neurologic disease\n\* Patients on an unstable hypoglycemic or lipid-lowering drug regime or patients on a drug regimen for less than 3 months, and patients taking medication that may affect serum parameters tested",  
 "healthyVolunteers": false,  
 "sex": "ALL",  
 "minimumAge": "30 Years",  
"stdAges": [  
"ADULT",  
"OLDER\_ADULT"  
]

Question:  
Based on the following clinical trial information, would a patient with a ALK gene mutation be eligible for the clinical trial?

Answer:  
This trial is for type 2 diabetes management using a product called Cinnamonforce. The information provided about the patient having an ALK gene mutation is irrelevant to the inclusion/exclusion criteria. Having the ALK mutation doesn't automatically disqualify them, but it also doesn't qualify them. They would need to meet \*all\* of the other inclusion criteria and \*none\* of the exclusion criteria to be eligible.